Trial
NCT03519308
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Abramson Cancer Center at Penn Medicine
Collaborators
—
Condition
Pancreatic Cancer
Intervention
Nivolumab
Why stopped
The accrual goal could not be met and the drug manufacturer pulled support
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-03-15